{"id":139439,"date":"2023-01-30T04:05:33","date_gmt":"2023-01-30T09:05:33","guid":{"rendered":"https:\/\/44.250.171.167\/?p=139439"},"modified":"2023-01-30T04:05:34","modified_gmt":"2023-01-30T09:05:34","slug":"laurus-labs-limited-q3-fy23-consolidated-revenue-jumps-by-50","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy23-consolidated-revenue-jumps-by-50\/","title":{"rendered":"Laurus Labs Limited Q3 FY23; Consolidated Revenue Jumps By 50%"},"content":{"rendered":"

Laurus Labs Limited<\/a> (NSE: LAURUSLABS<\/a>) reported Revenue from Operations for Q3 FY23 of \u20b91,544.82 Crore up from \u20b91028.76 Crore year on year, a growth of 50%. Consolidated Net Profit of \u20b9277.85 Crore, up 31% from \u20b9154.97 Crore in the same quarter of the previous year. The Earnings per Share is \u20b93.76 for this quarter.<\/p>\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Laurus Labs Limited (NSE: LAURUSLABS) reported Revenue from Operations for Q3 FY23 of \u20b91,544.82 Crore up from \u20b91028.76 Crore year on year, a growth of 50%. Consolidated Net Profit of \u20b9277.85 Crore, up 31% from \u20b9154.97 Crore in the same quarter of the previous year. The Earnings per Share is \u20b93.76 for this quarter.<\/p>\n","protected":false},"author":1917,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[1115],"class_list":["post-139439","post","type-post","status-publish","format-standard","hentry","category-infographics","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":143078,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3fy23-net-profit-rises-by-32-percent\/","url_meta":{"origin":139439,"position":0},"title":"Laurus Labs Q3FY23 net profit rises by 32 percent","author":"Chirag Gupta","date":"March 1, 2023","format":false,"excerpt":"Pharmaceutical and biotechnology company Laurus Labs reported 32% year-on-year (YoY) rise in profit after tax to INR 203 crore for the quarter ended December 31, 2022. The company had reported a net profit of INR 155 crore in the same quarter, previous fiscal year. The company's consolidated revenue from operations\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"earnings preview","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":177358,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","url_meta":{"origin":139439,"position":1},"title":"Laurus Labs Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 23, 2026","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":144359,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q4fy23-earnings\/","url_meta":{"origin":139439,"position":2},"title":"Laurus Labs Limited Q4FY23 Earnings","author":"Karan_Singh","date":"April 27, 2023","format":false,"excerpt":"To meet the demands of the international pharmaceutical industry, Laurus Labs primarily provides a comprehensive and integrated portfolio of Active Pharmaceutical Ingredients (API), including intermediates, Generic Finished Dosage Forms (FDF), and Contract Research services. Financial Results: Laurus Labs Ltd. reported Total Income for Q4FY23 of \u20b9 1,382.61 Crores down from\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":139585,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":139439,"position":3},"title":"Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 31, 2023","format":false,"excerpt":"Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by growth in non-ARV revenues, especially CDMO and API, and recovery in ARV formulations that is expected to continue further. Q&A Highlights: [00:18:37] Sajal Kapoor asked about the anticipated\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131817,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":139439,"position":4},"title":"Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"July 29, 2022","format":false,"excerpt":"https:\/\/youtu.be\/gMXrmnAGz9Y Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace to pick up in FY23. In new markets, the company validated two products as part of CMO opportunity and expects significant upside in FY23 from these products. Q&A\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166795,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q3fy25-304-rise-in-profits\/","url_meta":{"origin":139439,"position":5},"title":"Laurus Labs Ltd Q3FY25; 304% rise in Profits","author":"Chirag Gupta","date":"February 11, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/139439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1917"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=139439"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/139439\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=139439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=139439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=139439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}